Jazz Pharmaceuticals has posted fresh phase 2 data on zanidatamab that show the HER2-targeted bispecific antibody kept 59% of ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

HER2 overexpression in patients with nonmuscle-invasive bladder cancer independently predicts worse response to intravesical BCG therapy.

During a Community Case Forum series, breast cancer experts discussed the importance of testing for ESR1 mutations, in ...

Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery ...

Patients with early breast cancer treated with presurgical endocrine therapy or chemotherapy plus Herceptin and Perjeta ...

The Food and Drug Administration approved ribociclib plus an aromatase inhibitor for hormone receptor (HR)–positive, ...

Findings from the NATALEE trial show that the combination of Kisqali and an aromatase inhibitor resulted in disease-free ...

A recent study uncovers the molecular signatures of mammographic calcifications in hormone receptor-positive, HER2-negative ...

TNBC patients with pCRs had a 5-year event-free survival (EFS) rate of 92% with the addition of ICIs versus 88% without them.

The FDA approved ribociclib (Kisqali) for adjuvant treatment of high-risk, hormone receptor-positive, HER2-negative early breast cancer ... outcome was measured by the invasive disease-free survival ...

Superior efficacy at 12 weeks was seen with the frontline combination of abemaciclib and endocrine therapy vs standard ...